Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20

1.

Fenretinide differentially modulates the levels of long- and very long-chain ceramides by downregulating Cers5 enzyme: evidence from bench to bedside.

Garić D, De Sanctis JB, Wojewodka G, Houle D, Cupri S, Abu-Arish A, Hanrahan JW, Hajduch M, Matouk E, Radzioch D.

J Mol Med (Berl). 2017 Oct;95(10):1053-1064. doi: 10.1007/s00109-017-1564-y. Epub 2017 Jul 10.

PMID:
28695226
2.

High-fat diet modifies the PPAR-γ pathway leading to disruption of microbial and physiological ecosystem in murine small intestine.

Tomas J, Mulet C, Saffarian A, Cavin JB, Ducroc R, Regnault B, Kun Tan C, Duszka K, Burcelin R, Wahli W, Sansonetti PJ, Pédron T.

Proc Natl Acad Sci U S A. 2016 Oct 4;113(40):E5934-E5943. Epub 2016 Sep 16.

3.

Ineffective correction of PPARγ signaling in cystic fibrosis airway epithelial cells undergoing repair.

Bou Saab J, Bacchetta M, Chanson M.

Int J Biochem Cell Biol. 2016 Sep;78:361-369. doi: 10.1016/j.biocel.2016.07.035. Epub 2016 Jul 30.

PMID:
27484450
4.

Phosphatidylcholine passes through lateral tight junctions for paracellular transport to the apical side of the polarized intestinal tumor cell-line CaCo2.

Stremmel W, Staffer S, Gan-Schreier H, Wannhoff A, Bach M, Gauss A.

Biochim Biophys Acta. 2016 Sep;1861(9 Pt A):1161-1169. doi: 10.1016/j.bbalip.2016.06.019. Epub 2016 Jun 27.

5.

Stimulation of nuclear receptor peroxisome proliferator-activated receptor-γ limits NF-κB-dependent inflammation in mouse cystic fibrosis biliary epithelium.

Scirpo R, Fiorotto R, Villani A, Amenduni M, Spirli C, Strazzabosco M.

Hepatology. 2015 Nov;62(5):1551-62. doi: 10.1002/hep.28000. Epub 2015 Aug 28.

6.

Progressive familial intrahepatic cholestasis.

Srivastava A.

J Clin Exp Hepatol. 2014 Mar;4(1):25-36. doi: 10.1016/j.jceh.2013.10.005. Epub 2013 Nov 23. Review.

7.

Nebulized hyaluronan ameliorates lung inflammation in cystic fibrosis mice.

Gavina M, Luciani A, Villella VR, Esposito S, Ferrari E, Bressani I, Casale A, Bruscia EM, Maiuri L, Raia V.

Pediatr Pulmonol. 2013 Aug;48(8):761-71. doi: 10.1002/ppul.22637. Epub 2012 Jul 23.

PMID:
22825912
8.

PPARγ as a therapeutic target in cystic fibrosis.

Dekkers JF, van der Ent CK, Kalkhoven E, Beekman JM.

Trends Mol Med. 2012 May;18(5):283-91. doi: 10.1016/j.molmed.2012.03.004. Epub 2012 Apr 9. Review.

PMID:
22494945
9.

PPAR-γ agonists in polycystic kidney disease with frequent development of cardiovascular disorders.

Nagao S, Yamaguchi T.

Curr Mol Pharmacol. 2012 Jun;5(2):292-300. Review.

PMID:
22122459
10.

Pioglitazone Attenuates Cystic Burden in the PCK Rodent Model of Polycystic Kidney Disease.

Blazer-Yost BL, Haydon J, Eggleston-Gulyas T, Chen JH, Wang X, Gattone V, Torres VE.

PPAR Res. 2010;2010:274376. doi: 10.1155/2010/274376. Epub 2010 Nov 1.

11.

Cystic fibrosis: a disorder with defective autophagy.

Luciani A, Villella VR, Esposito S, Brunetti-Pierri N, Medina DL, Settembre C, Gavina M, Raia V, Ballabio A, Maiuri L.

Autophagy. 2011 Jan;7(1):104-6. Epub 2011 Jan 1.

PMID:
21048426
12.

Lipids control mucus production in cystic fibrosis.

Gulbins E.

Nat Med. 2010 Mar;16(3):267-8. doi: 10.1038/nm0310-267. No abstract available.

PMID:
20208510
13.

Pharmacological correction of a defect in PPAR-gamma signaling ameliorates disease severity in Cftr-deficient mice.

Harmon GS, Dumlao DS, Ng DT, Barrett KE, Dennis EA, Dong H, Glass CK.

Nat Med. 2010 Mar;16(3):313-8. doi: 10.1038/nm.2101. Epub 2010 Feb 14.

14.

SUMOylation of tissue transglutaminase as link between oxidative stress and inflammation.

Luciani A, Villella VR, Vasaturo A, Giardino I, Raia V, Pettoello-Mantovani M, D'Apolito M, Guido S, Leal T, Quaratino S, Maiuri L.

J Immunol. 2009 Aug 15;183(4):2775-84. doi: 10.4049/jimmunol.0900993. Epub 2009 Jul 22. Erratum in: J Immunol. 2014 Nov 15;193(10):5347-9.

15.

Activation of PPARgamma by rosiglitazone attenuates intestinal Cl- secretion.

Bajwa PJ, Lee JW, Straus DS, Lytle C.

Am J Physiol Gastrointest Liver Physiol. 2009 Jul;297(1):G82-9. doi: 10.1152/ajpgi.90640.2008. Epub 2009 May 14.

16.

PPARgamma agonists inhibit vasopressin-mediated anion transport in the MDCK-C7 cell line.

Nofziger C, Brown KK, Smith CD, Harrington W, Murray D, Bisi J, Ashton TT, Maurio FP, Kalsi K, West TA, Baines D, Blazer-Yost BL.

Am J Physiol Renal Physiol. 2009 Jul;297(1):F55-62. doi: 10.1152/ajprenal.00090.2009. Epub 2009 Apr 29.

17.

Tissue transglutaminase activation modulates inflammation in cystic fibrosis via PPARgamma down-regulation.

Maiuri L, Luciani A, Giardino I, Raia V, Villella VR, D'Apolito M, Pettoello-Mantovani M, Guido S, Ciacci C, Cimmino M, Cexus ON, Londei M, Quaratino S.

J Immunol. 2008 Jun 1;180(11):7697-705.

18.

Alterations in immune response and PPAR/LXR regulation in cystic fibrosis macrophages.

Andersson C, Zaman MM, Jones AB, Freedman SD.

J Cyst Fibros. 2008 Jan;7(1):68-78. Epub 2007 Sep 21.

19.
20.

Decreased expression of peroxisome proliferator activated receptor gamma in cftr-/- mice.

Ollero M, Junaidi O, Zaman MM, Tzameli I, Ferrando AA, Andersson C, Blanco PG, Bialecki E, Freedman SD.

J Cell Physiol. 2004 Aug;200(2):235-44.

PMID:
15174093

Supplemental Content

Loading ...
Support Center